A. Rationale The Virus Core is an essential resource for the needs of projects 1 and 2, which will benefit from a centralized Virus Core by: i) the established expertise with reverse genetics techniques which will facilitate rescue of recombinant influenza viruses that are described below and itemized in Table 1B, ii) the maintenance of influenza virus stocks that have been sequence-confirmed and assessed for quality by hemagglutination and plaque assays, and iii) reduced inter-experimental variation by consistent use of specific virus stock preparations. The Department of Microbiology, Mount Sinai School of Medicine, NY, NY is a pioneer in the application of reverse genetics and the development of recombinant viruses. The well equipped facilities, established procedures, and properly trained personnel provide a cost-effective Virus Core that will result in efficient production of wild-type and recombinant influenza virus stocks that will be essential for projects 1 and 2. Specifically, Dr. Megan Shaw (Co-PI of project 1) and Dr. Adolfo Garcia-Sastre (Co-PI of project 2) will directly benefit by their close proximity to and direct communication with the Virus Core. B, Specific functions of the Virus Core 1) Maintain working stocks of wild-type influenza viruses for use by projects 1 and 2. 2) Generate recombinant influenza viruses for use by projects 1 and 2.

Public Health Relevance

Core G: Virus Core is an essential resource for the needs of projects 1 and 2, which will benefit from: i) the established expertise with reverse genetics techniques which will facilitate rescue of recombinant influenza viruses, ii) the maintenance of sequence-confirmed, high tittered influenza virus stocks, and iii) reduced inter-experimental variation by consistent use of specific virus stock preparations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI106754-01
Application #
8580825
Study Section
Special Emphasis Panel (ZAI1-EC-M (M1))
Project Start
Project End
Budget Start
2013-06-26
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$109,894
Indirect Cost
$18,160
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Schotsaert, Michael; García-Sastre, Adolfo (2016) A High-Resolution Look at Influenza Virus Antigenic Drift. J Infect Dis 214:982
Hultquist, Judd F; Schumann, Kathrin; Woo, Jonathan M et al. (2016) A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. Cell Rep 17:1438-1452
Heaton, Nicholas S; Moshkina, Natasha; Fenouil, Romain et al. (2016) Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity 44:46-58
Tripathi, Shashank; Garcia-Sastre, Adolfo (2016) Antiviral innate immunity through the lens of systems biology. Virus Res 218:10-7
Muñoz-Moreno, Raquel; Cuesta-Geijo, Miguel Ángel; Martínez-Romero, Carles et al. (2016) Antiviral Role of IFITM Proteins in African Swine Fever Virus Infection. PLoS One 11:e0154366
Rialdi, Alex; Campisi, Laura; Zhao, Nan et al. (2016) Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science 352:aad7993
Shah, Priya S; Wojcechowskyj, Jason A; Eckhardt, Manon et al. (2015) Comparative mapping of host-pathogen protein-protein interactions. Curr Opin Microbiol 27:62-8
Ayllon, Juan; García-Sastre, Adolfo (2015) The NS1 protein: a multitasking virulence factor. Curr Top Microbiol Immunol 386:73-107
Cooper, Daphne A; Banerjee, Shuvojit; Chakrabarti, Arindam et al. (2015) RNase L targets distinct sites in influenza A virus RNAs. J Virol 89:2764-76
Miller, Matthew S; Rialdi, Alexander; Ho, Jessica Sook Yuin et al. (2015) Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis. Nat Immunol 16:485-94

Showing the most recent 10 out of 20 publications